In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.

@article{IdnpnHeikkil1997InMR,
  title={In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.},
  author={J. J. Id{\"a}np{\"a}{\"a}n-Heikkil{\"a} and Serge Perrot and Gis{\`e}le Guilbaud and Val{\'e}rie Kayser},
  journal={European journal of pharmacology},
  year={1997},
  volume={325 2-3},
  pages={155-64}
}
The ability of the selective cholecystokinin(B) (CCK(B)) receptor antagonist L-365,260 (0.2 mg/kg s.c.) to modulate the antinociceptive action of relatively low doses of systemic morphine (0.1, 0.3 and 1.0 mg/kg i.v.) was evaluated using a well established rat model of peripheral unilateral mononeuropathy. Behavioural tests based on both mechanical (vocalization threshold to paw pressure) and thermal (struggle latency after immersion of the paw into a cold (10 degrees C), warm (44 degrees C) or… CONTINUE READING